Please assess the completion status of the following clinical trial:

Trial Title: Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetes on diet and exercise therapy or monotherapy with metformin, insulin secretagogue, or alpha-glucosidase inhibitors, or a low-dose combination of these at ≤ 50% maximal dose (see Appendix). Dosing is stable for 8 weeks prior to randomization.~2. FPG ≤ 225 mg/dL and HbA1c\>7% and ≤9.5% at screening~3. Age ≥18 and \<75~4. Women of childbearing potential agree to use an appropriate contraceptive method (hormonal, IUD, or diaphragm)~Exclusion Criteria:~1. Type 1 diabetes and/or history of ketoacidosis determined by medical history~2. History of severe diabetic neuropathy including autonomic neuropathy, gastroparesis or lower limb ulceration or amputation~3. History of long-term therapy with insulin (\>30 days) within the last year~4. Therapy with rosiglitazone (Avandia) or pioglitazone (Actos), or extendin-4 (Byetta), alone or in combination in the previous 6 months~5. Pregnancy or lactation~6. Patients requiring corticosteroids within 3 months or recurrent continuous oral corticosteroid treatment (more than 2 weeks)~7. Use of weight loss drugs \[e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications\] within 3 months of screening or intentional weight loss of ≥ 10 lbs in the previous 6 months~8. Surgery within 30 days prior to screening~9. Serum creatinine \>1.4 for women and \>1.5 for men or eGFR \<60 \[possible chronic kidney disease stage 3 or greater calculated using the Modification of Diet in Renal Disease (MDRD) equation.~10. History of chronic liver disease including hepatitis B or C~11. History of peptic ulcer or endoscopy demonstrated gastritis~12. History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)~13. History of malignancy, except participants who have been disease-free for greater than 10 years, or whose only malignancy has been basal or squamous cell skin carcinoma~14. New York Heart Association Class III or IV cardiac status or hospitalization for congestive heart failure~15. History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack or any revascularization within 6 months~16. Uncontrolled hypertension (defined as systolic blood pressure \>150 mmHg or diastolic blood pressure \>95 mmHg on three or more assessments on more than one day)~17. History of drug or alcohol abuse, or current weekly alcohol consumption \>10 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol)~18. Hemoglobin \<12 g/dL (males), \<10 g/dL (females) at screening~19. Platelets \<100,000 cu mm at screening.~20. AST (SGOT) \>2.50 x ULN or ALT (SGPT) \>2.50 x ULN at screening~21. Total Bilirubin \>1.50 x ULN at screening~22. Triglycerides (TG) \>500 mg/dL at screening~23. Poor mental function or any other reason to expect patient difficulty in complying with the requirements of the study~24. Previous allergy to aspirin~25. Chronic or continuous use (daily for more than 7 days) of nonsteroidal anti-inflammatory drugs within the preceding 2 months~26. Use of warfarin (Coumadin), clopidogrel (Plavix) or other anticoagulants~27. Use of probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, appearance matched to active drug
- 3 gram (Type: ACTIVE_COMPARATOR): Salsalate 3.0 grams daily, divided
- 3.5 gram (Type: ACTIVE_COMPARATOR): Salsalate 3.5 g daily, divided
- 4 gram (Type: ACTIVE_COMPARATOR): Salsalate 4.0 g daily, divided

Based on this trial design, predict the completion outcome and termination type (if applicable).